$SEGG provided an update on its previously announced 90-day execution plan, reaffirming its near-term focus on completing announced acquisitions, strengthening core operations, and allocating capital with discipline and accountability.

$SATL NASA's Commercial Satellite Data Acquisition Program Releases Archived And Tasked Multispectral Data From Satellogic

$RDW announce the launch of the T-REX 2X Long RDW Daily Target ETF , a leveraged ETF providing 2x daily long exposure to Redwire Corporation $RDW

$RARE has resubmitted its biologics license application for accelerated approval of gene therapy UX111 to treat Sanfilippo syndrome type A to the US Food and Drug Administration.

Polymarket's "What price will Bitcoin hit in 2026?" market has drawn serious liquidity with over $10M in volume. $150,000 Target: 18% probability $100,000 Target: 71% probability $75,000 Target: 78% probability $55,000 Target: 41% probability $45,000 Target: 28% probability

$AI Reports said the enterprise AI software maker is in talks to be acquired by Automation Anywhere, a privately held automation software company that could use the transaction to go public.

US stocks slide as investors fret over Trump's Fed nominee, earnings, inflation

#OpenAI Plans Fourth Quarter IPO in Race to Beat #Anthropic to Market

GCT Semiconductor Holding $GCTS said it licensed its 5G and 4G chipsets to "one of the world's largest satellite communications providers," enabling integration into the client's user equipment.

$BCAB BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction. $BCAB leads Phase 3 trial execution for Oz-V in OPSCC through data readout for potential accelerated approval and enrollment anticipated to begin early 2026.

$BCAB BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.

$QNCX company to cease clinical development of eDSP; Intends to preserve cash and explore available options

$QNCX Resume trading 3:30pm

$GUTS hinted at a change in its U.S. regulatory strategy for Revita. Fractyl requested FDA feedback on potentially reclassifying Revita under the De Novo pathway, rather than a Premarket Approval (PMA).

$QNCX Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia Primary and key secondary endpoint did not achieve statistical significance

Alibaba Group's $BABA logistics arm Cainiao is buying a stake in Chinese robovan specialist Zelos Technology and merging its autonomous driving unit with Zelos

$SLDP Solid Power said the common warrants will be immediately exercisable at an exercise price of $7.25 per share, and will expire seven years after issuance. The offering is expected to be completed by Thursday

$SLDP Gross proceeds of $130 million, is priced at $5.70 per share and accompanying two common warrants, and $5.699 per pre-funded warrant and accompanying two common warrants

$SLDP Solid Power has priced a registered direct offering of 17M shares, pre-funded warrants to purchase 5.8M shares, and warrants to purchase up to 45.6M shares.

$ARDX Ardelyx dosed the first patient in the Accel phase 3 trial evaluating the safety and efficacy of Ibsrela to treat chronic idiopathic constipation in adults. The trial will enroll about 700 patients with chronic idiopathic constipation